Cadila Pharmaceuticals Launches 10 Innovative Products in 2023

Ahmedabad, June 27, 2023: Cadila Pharmaceuticals, a leading pharmaceutical company committed to improving global healthcare, proudly announces the successful launch of 10 cutting-edge products from January 2023 to May 2023. These ground-breaking additions to our portfolio offer advanced solutions to address various medical conditions and further enhance patient care. 

1. Ferowall Tablet: The Ferowall Tablet combines Faropenem and Clavulanic Acid to provide a potent treatment for bacterial infections. 

2. Cadilyse T Chewable Tab: This tablet contains a unique combination of five enzymes to support the digestion and absorption of food containing protein, carbohydrates, and fats. 

3. Yunara Tablet: Yunara Tablet features a powerful blend of L-Glutathione, Grape Seed Extract, Alpha Lipoic Acid, and Astaxanthin. This formulation helps protect the skin from free radicals and damage caused by UV rays. 

4. Cadilyse Syrup: Developed to treat digestive disorders, Cadilyse Syrup contains Diastase and Pepsin to ensure proper digestion of starch or carbohydrates. 

5. Tarzed 150: Tarzed 150 is an injectable medication used in the treatment of HER2-positive breast cancer, both in its early and advanced stages. 

6. Esiloc D: This capsule combines Esomeprazole EC and Domperidone EC to provide effective relief for gastrointestinal reflux disease (GERD). 

7. Oxybro N: Oxybro N tablet is designed to treat and prevent asthma and symptoms of chronic obstructive pulmonary disease (COPD). 

8. Haem Up XT+: Haem Up XT+ tablets are formulated with sustained-release Ferrous Ascorbate (CR) and LMF to effectively address anaemia, poor diet and folate deficiency. 

9. Bactocad CA: Bactocad CA is an injection containing Avibactum and Ceftazidime, offering a powerful combination for the treatment of complicated intra- abdominal, Urinary tract infections. 

10. Cadeltro 25 & 50: Cadeltro 25 & 50 tablets contain Eltrombopag, which helps increase the number of platelets in the body, reducing the risk of bleeding in people with ITP or aplastic anaemia. 

These ground-breaking products demonstrate Cadila Pharmaceuticals’ ongoing commitment to delivering innovative healthcare solutions and improving patient outcomes. Each product has been meticulously formulated and tested to meet the highest quality standards, ensuring safety and efficacy. 

For more information about these products and our complete range of pharmaceutical solutions, please contact the customer support team.

Corporate Comm India (CCI Newswire)